Early Diagnosis and Treatment of Autism Being Explored

RIDGEFIELD, Conn. - Oct. 9, 2015 - PRLog -- Researchers at MMT NeuroTech www.MilMag.net are investigating the efficacy of combining neuroimaging and specific intervention in the early diagnosis and treatment of Autism Spectrum Disorder (ASD). A number of clinical studies have already established that early diagnosis (18 months) is possible. Further, researchers have documented that early commencement of treatment is of benefit to these young children with ASD.  Previous published research has reported that neuroimaging (MRI, fMRI, NIRS) can assist in the early diagnosis of ASD, allowing for early and thereby more effective treatment decisions for these children.
“Autism is a spectrum of developmental disorders (ASD) with profound disabilities in communication skills. Little is known about the brain organization that underlies early communication skills and their development. ASDs are estimated to affect 1 in 68 to 88 children, and it appears that the disease incidence is growing,” stated Dr. Donald Marks, the founder and Chief Science Officer for MMT NeuroTech.  “Early behavioral interventions have been shown to ameliorate early language and communication symptoms of ASD, suggesting that social interactions could have an impact on the development of the neural circuits involved, and that early intervention can be of benefit.”

Dr. Steven Levy, CEO of MMT Neurotech, adds, “We are hopeful that the assessment paradigms we are developing will allow access to very early treatment and therefore the potential of some reversal of the disease.”

MMT Neurotech / Millennium Magnetic Technologies is a commercial stage neuroimaging company holding the only issued patent on the association of real-time thought processes or thinking with specific neural activation patterns in the brain.  This allows for evaluation of a number of issues including objectively documenting the presence of pain for personal injury and disability claims, establishing fibromyalgia, identifying depression and suicidal ideation, monitoring for deception or lie detection during forensic interrogation with greater than 90% accuracy, real-time memory recordings, as well as providing the earliest possible diagnosis and therefore treatment of Autism Spectrum Disorders and pre-Alzheimer’s disease.

For more information about MMT Neurotech contact: Steven Levy MD  SL@MilMag.net  or Donald H. Marks MD PhD DHM@MilMag.net    MMT NeuroTech www.MilMag.net  is a New Jersey / Connecticut neurotechnology company which commercializes disruptive neuroimaging technologies to image thought.